An interventional study of foot insole in Diabetic Foot Ulcer, sponsored by Cairo University. Enrolling by invitation at 1 site in Egypt. Open to participants aged 50 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-05.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Diabetic Foot with a site in Egypt — 7 open to participants now, 8 under way, none of them phase 3. Diabetic Foot · Egypt.
Among the 30 studies in Diabetic Foot with a site in Egypt, this one is the 9th largest by planned enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2021, is one of 21 with no phase, and was the 12th registered.
1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.
Browse Diabetic Foot studies →7 of the 30 studies in Diabetic Foot with a site in Egypt are open now. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 30–75
Al Hayah University In Cairo · Sites in Egypt
Ages 18–65
Cairo University · Sites in Egypt
Ages 40–70
Beni-Suef University · Sites in Egypt
Ages 50–65
Cairo University · Sites in Egypt
Ages 45–55
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 50 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 849 interventional studies indexed under Diabetic Foot.
Median enrollment 49 across the 26 interventional studies, 60 across the 4 observational. Of the 18 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 30 have an industry lead sponsor. The 10 most frequent:
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Cairo University has 8 studies filed under Diabetic Foot — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetic Foot with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06916663Al Hayah University In CairoRCT Comparing Upper Body vs. Combined Exercise Protocols During Active Diabetic Foot Ulcer Treatment | 2027-04-23 |
| NCT07768228Ain Shams UniversityThe Effect of L-Carnitine on Wound Healing in Patients With Diabetic Foot Ulcer. | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies in Diabetic Foot with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to find out the changes in peak pressure and pressure-time integral after twelve weeks from the initial utility of foot insoles and eight weeks later as a follow-up in diabetic foot ulcers. Participants will be randomly assigned to foot insole, medication, and wound care (study group) or medication and wound care (control group).
Insole design The foot insole is 5 mm thick under the flat part of the forefoot and the modification is done by changing the position of the metatarsal bar. This was another 5 mm above the flat part of the foot insole. The proximal/distal position of the metatarsal rod and the cavity distal to the rod (large cavity) were defined using the plantar pressure distribution. The position and shape of the distal end of the metatarsal bar were defined by a line in the area where the plantar pressure was 75% of the maximum plantar pressure. This line also defined the void's proximal border. The void's distal border was housed near the area of peak plantar pressures, where pressure was 10% of peak plantar pressure. The void measured 3 mm in depth. After completing the initial design of the metatarsal bars and void, two variations were created by relocating the metatarsal bar proximal and distal by 2-4% of the insole length depending on the position of the foot ulcer. Based on a previous pilot study, this proportion equates to a distance of 5-7 mm on a size 38 orthotic insole. The orthotic insoles were made of medium-density (Ethylene-vinyl acetate) EVA (50° Shore A) and were manufactured on a CNC machine.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pressure maps were recorded to calculate peak pressures and pressure-time integrals for (hindfoot, middle foot, hallux, medial forefoot, and lateral forefoot). The measurements were uploaded to a server of software that uses technology to create a 3D model of the foot insole from multiple images taken by the user.
Other: foot insole
participants will receive only medical treatments and wound care for the diabetic foot ulcer
Other: foot insole
The foot insole is 5 mm thick under the flat part of the forefoot and the modification is done by changing the position of the metatarsal bar. This was another 5 mm above the flat part of the foot insole. The proximal/distal position of the metatarsal rod and the cavity distal to the rod (large cavity) were defined using the plantar pressure distribution. The position and shape of the distal end of the metatarsal bar were defined by a line in the area where the plantar pressure was 75% of the maximum plantar pressure The void measured 3 mm in depth.
peak pressures
peak pressure for hindfoot, midfoot, hallux, medial and lateral forefoot
Time frame: 12 weeks
pressure-time integrals
pressure time integral for hindfoot, midfoot, hallux, medial, and lateral forefoot
Time frame: 12 weeks
Plan to share: No
Started Sep 2021 (actual). Primary completion is estimated for Jul 2023, 21 months after the start.
Of 243 non-industry interventional studies with no phase under Diabetic Foot, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 21 months is close to that.
Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.